Article Information
History
- January 20, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Paul A Goepfert1,
- Bo Fu2,
- Anne-Laure Chabanon3,
- Matthew I Bonaparte2,
- Matthew G Davis4,
- Brandon J Essink5,
- Ian Frank6,
- Owen Haney2,
- Helene Janosczyk2,
- Michael C Keefer7,
- Marguerite Koutsoukos8,
- Murray A Kimmel9,
- Roger Masotti2,
- Stephen J Savarino2,
- Lode Schuerman8,
- Howard Schwartz10,
- Lawrence D Sher11,
- Jon Smith2,
- Fernanda Tavares-Da-Silva8,
- Sanjay Gurunathan2,
- Carlos A DiazGranados2 and
- Guy De Bruyn2,*
- 1Department of Medicine, University of Alabama at Birmingham
- 2Sanofi Pasteur, Swiftwater, PA, USA
- 3Sanofi Pasteur, Lyon, France
- 4Rochester Clinical Research, Rochester, NY, USA
- 5Meridian Clinical Research, Omaha, NE, USA
- 6Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- 7University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA
- 8GlaxoSmithKline Vaccines, Wavre, Belgium
- 9Optimal Research LLC, Melbourne, FL, USA
- 10Research Centers of America, Hollywood, FL, USA
- 11Peninsula Research Associates, Rolling Hills Estates, CA, USA
- ↵*Corresponding Author:
Guy de Bruyn, Sanofi Pasteur, Swiftwater, PA, USA, Guy.DeBruyn{at}sanofi.com; Tel: +15709725671
Posted January 20, 2021.
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study
